The Role of [18F]FDG PET/CT in Predicting Toxicity in Patients with NHL Treated with CAR-T: A Systematic Review

IF 4.7 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-06-03 DOI:10.3390/tomography10060066

N. Quartuccio, Salvatore Ialuna, S. Pulizzi, Dante D’Oppido, Stefania Nicolosi, Antonino Maria Moreci

{"title":"The Role of [18F]FDG PET/CT in Predicting Toxicity in Patients with NHL Treated with CAR-T: A Systematic Review","authors":"N. Quartuccio, Salvatore Ialuna, S. Pulizzi, Dante D’Oppido, Stefania Nicolosi, Antonino Maria Moreci","doi":"10.3390/tomography10060066","DOIUrl":null,"url":null,"abstract":"CAR-T-cell therapy, also referred to as chimeric antigen receptor T-cell therapy, is a novel method in the field of immunotherapy for the treatment of non-Hodgkin’s lymphoma (NHL). In patients receiving CAR-T-cell therapy, fluorodeoxyglucose Positron Emission Tomography/Computer Tomography ([18F]FDG PET/CT) plays a critical role in tracking treatment response and evaluating the immunotherapy’s overall efficacy. The aim of this study is to provide a systematic review of the literature on the studies aiming to assess and predict toxicity by means of [18F]FDG PET/CT in patients with NHL receiving CAR-T-cell therapy. PubMed/MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) databases were interrogated by two investigators to seek studies involving the use of [18F]FDG PET/CT in patients with lymphoma undergoing CAR-T-cell therapy. The comprehensive computer literature search allowed 11 studies to be included. The risk of bias for the studies included in the systematic review was scored as low by using version 2 of the “Quality Assessment of Diagnostic Accuracy Studies” tool (QUADAS-2). The current literature emphasizes the role of [18F]FDG PET/CT in assessing and predicting toxicity in patients with NHL receiving CAR-T-cell therapy, highlighting the evolving nature of research in CAR-T-cell therapy. Additional studies are warranted to increase the collected evidence in the literature.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":"48 51","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/tomography10060066","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

CAR-T-cell therapy, also referred to as chimeric antigen receptor T-cell therapy, is a novel method in the field of immunotherapy for the treatment of non-Hodgkin’s lymphoma (NHL). In patients receiving CAR-T-cell therapy, fluorodeoxyglucose Positron Emission Tomography/Computer Tomography ([18F]FDG PET/CT) plays a critical role in tracking treatment response and evaluating the immunotherapy’s overall efficacy. The aim of this study is to provide a systematic review of the literature on the studies aiming to assess and predict toxicity by means of [18F]FDG PET/CT in patients with NHL receiving CAR-T-cell therapy. PubMed/MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) databases were interrogated by two investigators to seek studies involving the use of [18F]FDG PET/CT in patients with lymphoma undergoing CAR-T-cell therapy. The comprehensive computer literature search allowed 11 studies to be included. The risk of bias for the studies included in the systematic review was scored as low by using version 2 of the “Quality Assessment of Diagnostic Accuracy Studies” tool (QUADAS-2). The current literature emphasizes the role of [18F]FDG PET/CT in assessing and predicting toxicity in patients with NHL receiving CAR-T-cell therapy, highlighting the evolving nature of research in CAR-T-cell therapy. Additional studies are warranted to increase the collected evidence in the literature.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

18F]FDG PET/CT 在预测 CAR-T 治疗的 NHL 患者的毒性中的作用：系统性综述

CAR-T 细胞疗法又称嵌合抗原受体 T 细胞疗法，是免疫疗法领域治疗非霍奇金淋巴瘤（NHL）的一种新方法。在接受 CAR-T 细胞疗法的患者中，氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（[18F]FDG PET/CT）在跟踪治疗反应和评估免疫疗法的总体疗效方面发挥着至关重要的作用。本研究的目的是对旨在通过[18F]FDG PET/CT评估和预测接受CAR-T细胞疗法的NHL患者毒性的研究文献进行系统综述。两位研究人员查询了 PubMed/MEDLINE 和 Cochrane 对照试验中央注册数据库 (CENTRAL)，寻找有关在接受 CAR-T 细胞疗法的淋巴瘤患者中使用 [18F]FDG PET/CT 的研究。通过全面的计算机文献检索，共纳入了 11 项研究。采用第二版 "诊断准确性研究质量评估 "工具（QUADAS-2）对纳入系统综述的研究进行评分，结果显示偏倚风险较低。目前的文献强调了[18F]FDG PET/CT在评估和预测接受CAR-T细胞疗法的NHL患者毒性方面的作用，突出了CAR-T细胞疗法研究不断发展的性质。有必要开展更多研究，以增加文献中收集的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.